166 related articles for article (PubMed ID: 27707765)
1. Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax.
Chen WH; Pasetti MF; Adhikari RP; Baughman H; Douglas R; El-Khorazaty J; Greenberg N; Holtsberg FW; Liao GC; Reymann MK; Wang X; Warfield KL; Aman MJ
Clin Vaccine Immunol; 2016 Dec; 23(12):918-925. PubMed ID: 27707765
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults.
Landrum ML; Lalani T; Niknian M; Maguire JD; Hospenthal DR; Fattom A; Taylor K; Fraser J; Wilkins K; Ellis MW; Kessler PD; Fahim RE; Tribble DR
Hum Vaccin Immunother; 2017 Apr; 13(4):791-801. PubMed ID: 28010246
[TBL] [Abstract][Full Text] [Related]
3. Oral vaccine formulations stimulate mucosal and systemic antibody responses against staphylococcal enterotoxin B in a piglet model.
Inskeep TK; Stahl C; Odle J; Oakes J; Hudson L; Bost KL; Piller KJ
Clin Vaccine Immunol; 2010 Aug; 17(8):1163-9. PubMed ID: 20554806
[TBL] [Abstract][Full Text] [Related]
4. High Titer Persistent Neutralizing Antibodies Induced by TSST-1 Variant Vaccine Against Toxic Shock Cytokine Storm.
Roetzer A; Stich N; Model N; Schwameis M; Firbas C; Jilma B; Eibl MM
Toxins (Basel); 2020 Oct; 12(10):. PubMed ID: 33023185
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity Evaluation of Recombinant Staphylococcus aureus Enterotoxin B (rSEB) and rSEB-loaded Chitosan Nanoparticles Following Nasal Administration.
Hosseini SA; Nazarian S; Ebrahimi F; Hajizade A
Iran J Allergy Asthma Immunol; 2020 Apr; 19(2):159-171. PubMed ID: 32372629
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of the histidine-to-tyrosine staphylococcal enterotoxin B mutant protein in C3H/HeJ mice.
Savransky V; Pinelis D; Korolev S; Ionin B; Fegeding K
Toxicon; 2004 Mar; 43(4):433-8. PubMed ID: 15051407
[TBL] [Abstract][Full Text] [Related]
7. A highly neutralizing human monoclonal antibody targeting a novel linear epitope on staphylococcal enterotoxin B.
Fan H; Zhao L; Wang W; Yu F; Jing H; Yang Y; Zhang X; Zhao Z; Gou Q; Zhang W; Zou Q; Zhang J; Zeng H
Hum Vaccin Immunother; 2024 Dec; 20(1):2360338. PubMed ID: 38857905
[TBL] [Abstract][Full Text] [Related]
8. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.
Schmidt CS; White CJ; Ibrahim AS; Filler SG; Fu Y; Yeaman MR; Edwards JE; Hennessey JP
Vaccine; 2012 Dec; 30(52):7594-600. PubMed ID: 23099329
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines.
Lowell GH; Colleton C; Frost D; Kaminski RW; Hughes M; Hatch J; Hooper C; Estep J; Pitt L; Topper M; Hunt RE; Baker W; Baze WB
Infect Immun; 1996 Nov; 64(11):4686-93. PubMed ID: 8890226
[TBL] [Abstract][Full Text] [Related]
10. Staphylococcal enterotoxin B mutants (N23K and F44S): biological effects and vaccine potential in a mouse model.
Woody MA; Krakauer T; Stiles BG
Vaccine; 1997 Feb; 15(2):133-9. PubMed ID: 9066029
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B.
Larkin EA; Stiles BG; Ulrich RG
PLoS One; 2010 Oct; 5(10):e13253. PubMed ID: 20949003
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans.
Harro C; Betts R; Orenstein W; Kwak EJ; Greenberg HE; Onorato MT; Hartzel J; Lipka J; DiNubile MJ; Kartsonis N
Clin Vaccine Immunol; 2010 Dec; 17(12):1868-74. PubMed ID: 20943877
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-15 increases vaccine efficacy through a mechanism linked to dendritic cell maturation and enhanced antibody titers.
Saikh KU; Kissner TL; Nystrom S; Ruthel G; Ulrich RG
Clin Vaccine Immunol; 2008 Jan; 15(1):131-7. PubMed ID: 18045883
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
16. Passive therapy with humanized anti-staphylococcal enterotoxin B antibodies attenuates systemic inflammatory response and protects from lethal pneumonia caused by staphylococcal enterotoxin B-producing Staphylococcus aureus.
Karau MJ; Tilahun ME; Krogman A; Osborne BA; Goldsby RA; David CS; Mandrekar JN; Patel R; Rajagopalan G
Virulence; 2017 Oct; 8(7):1148-1159. PubMed ID: 27925510
[TBL] [Abstract][Full Text] [Related]
17. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.
Bernstein DI; Pasetti MF; Brady R; Buskirk AD; Wahid R; Dickey M; Cohen M; Baughman H; El-Khorazaty J; Maier N; Sztein MB; Baqar S; Bourgeois AL
Vaccine; 2019 Jan; 37(4):602-611. PubMed ID: 30563789
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults.
Nissen M; Marshall H; Richmond P; Shakib S; Jiang Q; Cooper D; Rill D; Baber J; Eiden J; Gruber W; Jansen KU; Emini EA; Anderson AS; Zito ET; Girgenti D
Vaccine; 2015 Apr; 33(15):1846-54. PubMed ID: 25707693
[TBL] [Abstract][Full Text] [Related]
19. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice.
Lowell GH; Kaminski RW; Grate S; Hunt RE; Charney C; Zimmer S; Colleton C
Infect Immun; 1996 May; 64(5):1706-13. PubMed ID: 8613381
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.
Eldridge JH; Staas JK; Meulbroek JA; Tice TR; Gilley RM
Infect Immun; 1991 Sep; 59(9):2978-86. PubMed ID: 1879922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
